Fatigue in multiple sclerosis: Multidimensional assessment and response to symptomatic treatment

Alfredo Romani, Roberto Bergamaschi, Elisa Candeloro, Enrico Alfonsi, Roberto Callieco, Vittorio Cosi

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Sixty relapsing-remitting multiple sclerosis (MS) patients were selected on the basis of their score on the Fatigue Severity Scale (FSS) and formed two groups: 40 patients (fatigued MS, MSf) scored above the 75th percentile of a previously assessed representative MS sample (100 patients), and 20 age- and sex-matched patients (nonfatigued MS patients; MSnf) scored below the 25th percentile. The patients underwent clinical evaluation (Expanded Disability Status Scale (EDSS)), further assessment of fatigue (Fatigue Impact Scale), scales evaluating depression (Hamilton Depression Rating Scale (HDRS) and Beck's Depression Inventory (BDI)) and neuropsychological tests. All patients were evaluated for muscle fatigability and central activation by means of a biomechanical test of sustained contraction; they also underwent somatosensory evoked potentials (SSEPs) and transcranial magnetic stimulation (TMS). The patients of the MSf subgroup were then randomized to one of the following two treatments: 4-aminopyridine (4-AP) 24 mg/day and fluoxetine (FLX) 20 mg/day. After a one-week titration this treatment proceeded for 8 weeks. At the end of the treatment, EDSS, fatigue and depression scores were further evaluated. At baseline, fatigue test scores consistently correlated with depression and cognitive test scores, but not with the fatigability test. Fatigue scores decreased in both treatment groups in a similar way. Due to the design of the study, this cannot be disjoined from a placebo effect. The changes of fatigue scores could not be predicted in the FLX group, whereas in the 4-AP group higher basal fatigability test scores were associated with greater reduction in fatigue scores.

Original languageEnglish
Pages (from-to)462-468
Number of pages7
JournalMultiple Sclerosis Journal
Volume10
Issue number4
DOIs
Publication statusPublished - Aug 2004

Fingerprint

Multiple Sclerosis
Fatigue
Depression
4-Aminopyridine
Fluoxetine
Therapeutics
Disability Evaluation
Relapsing-Remitting Multiple Sclerosis
Placebo Effect
Somatosensory Evoked Potentials
Transcranial Magnetic Stimulation
Neuropsychological Tests
Equipment and Supplies
Muscles

Keywords

  • 4-aminopyridine
  • Evoked potentials
  • Fatigability
  • Fatigue
  • Fluoxetine
  • Multiple sclerosis
  • Transcranial magnetic stimulation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Fatigue in multiple sclerosis : Multidimensional assessment and response to symptomatic treatment. / Romani, Alfredo; Bergamaschi, Roberto; Candeloro, Elisa; Alfonsi, Enrico; Callieco, Roberto; Cosi, Vittorio.

In: Multiple Sclerosis Journal, Vol. 10, No. 4, 08.2004, p. 462-468.

Research output: Contribution to journalArticle

@article{f826d240abcb4e4790115cfb0d1f6cd6,
title = "Fatigue in multiple sclerosis: Multidimensional assessment and response to symptomatic treatment",
abstract = "Sixty relapsing-remitting multiple sclerosis (MS) patients were selected on the basis of their score on the Fatigue Severity Scale (FSS) and formed two groups: 40 patients (fatigued MS, MSf) scored above the 75th percentile of a previously assessed representative MS sample (100 patients), and 20 age- and sex-matched patients (nonfatigued MS patients; MSnf) scored below the 25th percentile. The patients underwent clinical evaluation (Expanded Disability Status Scale (EDSS)), further assessment of fatigue (Fatigue Impact Scale), scales evaluating depression (Hamilton Depression Rating Scale (HDRS) and Beck's Depression Inventory (BDI)) and neuropsychological tests. All patients were evaluated for muscle fatigability and central activation by means of a biomechanical test of sustained contraction; they also underwent somatosensory evoked potentials (SSEPs) and transcranial magnetic stimulation (TMS). The patients of the MSf subgroup were then randomized to one of the following two treatments: 4-aminopyridine (4-AP) 24 mg/day and fluoxetine (FLX) 20 mg/day. After a one-week titration this treatment proceeded for 8 weeks. At the end of the treatment, EDSS, fatigue and depression scores were further evaluated. At baseline, fatigue test scores consistently correlated with depression and cognitive test scores, but not with the fatigability test. Fatigue scores decreased in both treatment groups in a similar way. Due to the design of the study, this cannot be disjoined from a placebo effect. The changes of fatigue scores could not be predicted in the FLX group, whereas in the 4-AP group higher basal fatigability test scores were associated with greater reduction in fatigue scores.",
keywords = "4-aminopyridine, Evoked potentials, Fatigability, Fatigue, Fluoxetine, Multiple sclerosis, Transcranial magnetic stimulation",
author = "Alfredo Romani and Roberto Bergamaschi and Elisa Candeloro and Enrico Alfonsi and Roberto Callieco and Vittorio Cosi",
year = "2004",
month = "8",
doi = "10.1191/1352458504ms1051oa",
language = "English",
volume = "10",
pages = "462--468",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Fatigue in multiple sclerosis

T2 - Multidimensional assessment and response to symptomatic treatment

AU - Romani, Alfredo

AU - Bergamaschi, Roberto

AU - Candeloro, Elisa

AU - Alfonsi, Enrico

AU - Callieco, Roberto

AU - Cosi, Vittorio

PY - 2004/8

Y1 - 2004/8

N2 - Sixty relapsing-remitting multiple sclerosis (MS) patients were selected on the basis of their score on the Fatigue Severity Scale (FSS) and formed two groups: 40 patients (fatigued MS, MSf) scored above the 75th percentile of a previously assessed representative MS sample (100 patients), and 20 age- and sex-matched patients (nonfatigued MS patients; MSnf) scored below the 25th percentile. The patients underwent clinical evaluation (Expanded Disability Status Scale (EDSS)), further assessment of fatigue (Fatigue Impact Scale), scales evaluating depression (Hamilton Depression Rating Scale (HDRS) and Beck's Depression Inventory (BDI)) and neuropsychological tests. All patients were evaluated for muscle fatigability and central activation by means of a biomechanical test of sustained contraction; they also underwent somatosensory evoked potentials (SSEPs) and transcranial magnetic stimulation (TMS). The patients of the MSf subgroup were then randomized to one of the following two treatments: 4-aminopyridine (4-AP) 24 mg/day and fluoxetine (FLX) 20 mg/day. After a one-week titration this treatment proceeded for 8 weeks. At the end of the treatment, EDSS, fatigue and depression scores were further evaluated. At baseline, fatigue test scores consistently correlated with depression and cognitive test scores, but not with the fatigability test. Fatigue scores decreased in both treatment groups in a similar way. Due to the design of the study, this cannot be disjoined from a placebo effect. The changes of fatigue scores could not be predicted in the FLX group, whereas in the 4-AP group higher basal fatigability test scores were associated with greater reduction in fatigue scores.

AB - Sixty relapsing-remitting multiple sclerosis (MS) patients were selected on the basis of their score on the Fatigue Severity Scale (FSS) and formed two groups: 40 patients (fatigued MS, MSf) scored above the 75th percentile of a previously assessed representative MS sample (100 patients), and 20 age- and sex-matched patients (nonfatigued MS patients; MSnf) scored below the 25th percentile. The patients underwent clinical evaluation (Expanded Disability Status Scale (EDSS)), further assessment of fatigue (Fatigue Impact Scale), scales evaluating depression (Hamilton Depression Rating Scale (HDRS) and Beck's Depression Inventory (BDI)) and neuropsychological tests. All patients were evaluated for muscle fatigability and central activation by means of a biomechanical test of sustained contraction; they also underwent somatosensory evoked potentials (SSEPs) and transcranial magnetic stimulation (TMS). The patients of the MSf subgroup were then randomized to one of the following two treatments: 4-aminopyridine (4-AP) 24 mg/day and fluoxetine (FLX) 20 mg/day. After a one-week titration this treatment proceeded for 8 weeks. At the end of the treatment, EDSS, fatigue and depression scores were further evaluated. At baseline, fatigue test scores consistently correlated with depression and cognitive test scores, but not with the fatigability test. Fatigue scores decreased in both treatment groups in a similar way. Due to the design of the study, this cannot be disjoined from a placebo effect. The changes of fatigue scores could not be predicted in the FLX group, whereas in the 4-AP group higher basal fatigability test scores were associated with greater reduction in fatigue scores.

KW - 4-aminopyridine

KW - Evoked potentials

KW - Fatigability

KW - Fatigue

KW - Fluoxetine

KW - Multiple sclerosis

KW - Transcranial magnetic stimulation

UR - http://www.scopus.com/inward/record.url?scp=4344702174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344702174&partnerID=8YFLogxK

U2 - 10.1191/1352458504ms1051oa

DO - 10.1191/1352458504ms1051oa

M3 - Article

C2 - 15327047

AN - SCOPUS:4344702174

VL - 10

SP - 462

EP - 468

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 4

ER -